Retatrutide is a novel investigational triple hormone receptor agonist that simultaneously targets GLP-1, GIP, and glucagon receptors. This unique triple agonist mechanism represents the next generation of incretin-based peptides. Research indicates it may have significant effects on metabolic parameters, body composition, and energy expenditure. The glucagon receptor activation differentiates it from dual agonists by potentially enhancing energy expenditure and lipid metabolism. Currently under extensive clinical investigation for metabolic research applications.